化合物Venadaparib T9430

Product Introduction
Bioactivity


英文名: Venadaparib

描述: Venadaparib (NOV140101) 是一种选择性和具有口服活性的 PARP 抑制剂，对 PARP1和 PARP2的 IC50分别为 1.4 和 1.0 nM。它可防止 DNA 单链断裂 (SSB) 的修复，可研究实体瘤。

体外活性: Venadaparib significantly inhibits PARP1-mediated PAR expression with an EC50?of 0.5 nM In DNA damage-induced Hela cells[1].

体内活性: Oral administration of Venadaparib significantly inhibits PAR(>90%) in tumor tissues until 24 hr post-dose in the germline BRCA1-mutated ovarian cancer PDX model. Venadaparib also dose-dependently inhibits potent tumor growth compared to the Olaparib treatment group[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 90 mg/mL (221.43 mM)


关键字: IDX 1197 | inhibit | PARP | Inhibitor | solid | NOV-140101 | IDX1197 | tumors | anticancer | Venadaparib | NOV 140101 | poly ADP ribose polymerase

相关产品: PARP1-IN-15 | PARP-1-IN-3 | Talazoparib tosylate | Niraparib tosylate monohyrate | Lerzeparib | YCH1899 | Polyporenic acid C | Fluzoparib | Olaparib | Serratenediol

相关库: Drug Repurposing Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Ovarian Cancer Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | DNA Damage & Repair Compound Library | Orally Active Compound Library

化合物Venadaparib T9430信息由TargetMol中国为您提供，如您想了解更多关于化合物Venadaparib T9430报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途